NVS - Novartis AG
89.88 0.00 (0.00%)
After hours: 6:37PM EST
| Previous Close | 89.02 |
| Open | 89.11 |
| Bid | 0.00 x 1400 |
| Ask | 91.00 x 900 |
| Day's Range | 89.07 - 89.99 |
| 52 Week Range | 72.30 - 92.39 |
| Volume | 2,351,443 |
| Avg. Volume | 2,442,563 |
| Market Cap | 209.318B |
| Beta (3Y Monthly) | 0.65 |
| PE Ratio (TTM) | 16.71 |
| EPS (TTM) | 5.38 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.94 (3.30%) |
| Ex-Dividend Date | 2018-03-06 |
| 1y Target Est | 99.00 |
- Reuters•5 hours ago
U.S. Medicare plans to track CAR-T cancer therapy outcomes
The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including a registry or clinical study to monitor how well patients fare for at least two years after treatment. New hospital payment terms from Medicare, the federal government healthcare program for the elderly and disabled, are expected later in the year. If the proposal is finalized, use of CAR-Ts for Medicare patients could continue to be limited to the largest regional cancer centers.
- Moody's•6 hours ago
Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc.
Announcement: Moody's announces completion of a periodic review of ratings of Biogen Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Biogen Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- MarketWatch•8 hours ago
Medicare would cover CAR-T therapies under new CMS proposal
Under a new proposal by the Centers for Medicare & Medicaid Services, the Medicare program would cover FDA-approved CAR-T therapies. CAR-T, or chimeric anitgen receptor T-cell, therapies use genetically-engineered immune cells called T cells to more specifically target cancer cells. CMS said the proposal, announced Friday, would require Medicare to cover the cancer treatment when it is offered in a CMS-approved registry or clinical study, as long as data is collected from the patients for at least two years after treatment. CMS said it plans to use the information to decide what treatments are most beneficial to patients and which CAR-T therapies to fund in the future. "Today's proposed coverage decision would improve access to this therapy while deepening CMS's understanding of how patients in Medicare respond to it, so the agency can ensure that it is paying for CAR T-cell therapy for cases in which the benefits outweigh the risks," said CMS Administrator Seema Varma in a statement. There are currently only two approved CAR-T therapies in the U.S., and both are very expensive. Novartis's Kymriah has a list price of $475,000, while and Gilead Sciences Inc.'s Yescarta is priced at $373,000. There is no national Medicare policy for covering the expensive new cancer treatment, so it is currently up to local Medicare administrative contractors to decide whether to pay for it. Shares of Novartis have gained 4.3% in the year to date, while shares of Gilead have gained 6.3%. The SPDR S&P Pharmaceuticals ETF has gained 13.5% and the S&P 500 has gained 10.4%.
- Market Realist•12 hours ago
What Are the Key Growth Drivers for GlaxoSmithKline in 2019?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth drivers On its fourth-quarter earnings conference call, GlaxoSmithKline (GSK) highlighted the prioritization of R&D (research and development)
- Zacks•yesterday
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
- Zacks•yesterday
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
- Benzinga•2 days ago
The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 13) Abbott Laboratories (NYSE: ABT ) Ionis Pharmaceuticals ...
- Financial Times•2 days ago
[$$] J&J and Novartis back cancer geneticist’s immunotherapy start-up
Siddhartha Mukherjee, the cancer geneticist and Pulitzer Prize-winning writer who is working on a novel way to expand immunotherapies for blood cancers, has raised $42m for his start-up Vor Biopharma. to attack cancer, by disabling blockers inside the body.
- Zacks•2 days ago
Conatus (CNAT) Completes Enrollment in Phase II NASH Study
Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.
- Zacks•2 days ago
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report
Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
- Reuters•2 days ago
Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin
(Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of ...
- Zacks•2 days ago
Top Research Reports for ExxonMobil, Merck & Danaher
Top Research Reports for ExxonMobil, Merck & Danaher
- Zacks•3 days ago
Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100
Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.
- Zacks•4 days ago
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
- Quartz•4 days ago
The roots of “servant leadership” management culture date back to Hermann Hesse and a young Hillary Clinton
What do Howard Schultz, Hermann Hesse, and Hillary Clinton have in common?
- The Wall Street Journal•5 days ago
[$$] Big Pharma’s Big Cancer Hope Is Fizzling
Drug companies have spent big on chimeric antigen receptor T-cells, or CAR-T, cancer therapies. The treatment involves a process whereby a patient’s T-cells are extracted, modified and reinserted into the body to fight cancer. The treatments are exciting from a scientific point of view and have provided significant clinical benefits to a small number of patients with severe and uncommon forms of cancer.
- Zacks•7 days ago
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports fourth-quarter results.
- Zacks•7 days ago
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
- Zacks•8 days ago
Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View
Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.
Motley Fool•8 days agoLigand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript
LGND earnings call for the period ending December 31, 2018.
- Zacks•9 days ago
Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19
Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.
- Reuters•9 days ago
Novartis CEO lauds Trump administration plan to overhaul rebates
Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines..
